Compare effect of furosemide inhalation versus placebo in patients with acute cardiogenic pulmonary edema

Evaluation of the effect of furosemide inhalation versus placebo in patients with acute cardiogenic pulmonary edema

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017101436753N1

Enrollment

120

Registered

2017-11-18

Start date

2017-09-28

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pulmonary oedema. Left ventricular failure

Interventions

Intervention 1: Control group: Normal Saline as a placebo will be prescribed through nebulizer in addition to routine treatment at the first 10 minutes. Intervention 2: Intervention group: 40 milligra

Treatment - Drugs

Control group: Normal Saline as a placebo will be prescribed through nebulizer in addition to routine treatment at the first 10 minutes.

Intervention group: 40 milligram of Furosemide is inhaled through nebulizer in addition to routine treatment at the first 10 minutes

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: All the patients with acute cardiogenic edema will be included in the study. Exclusion criteria: not willing to participate in the study, history of susceptibility to sulfa drugs, unstable hemodynamics; requiring mechanical ventilation; decreased consciousness, accompany with another illness requiring treatment in the first 10 minutes of treatment with digoxin, beta blocker, beta-agonist and calcium; need to have another inhaling treatment in the first 10 minutes and need to have non-invasive ventilation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Oxygen saturation. Timepoint: Baseline and 10 minutes after intervention. Method of measurement: Pulse oximeter.;Respiratory rate. Timepoint: Baseline and 10 minutes after intervention. Method of measurement: Number of breaths per minute.;Heart rate. Timepoint: Baseline and 10 minutes after intervention. Method of measurement: Heart beats at per minute.;Arterial blood gases. Timepoint: Baseline and 10 minutes after intervention. Method of measurement: Arterial blood gases test.;Dyspnea Severity. Timepoint: Baseline and 10 minutes after intervention. Method of measurement: MMRC Dyspnea Severity Scale.	—

Measure

Time frame

Oxygen saturation. Timepoint: Baseline and 10 minutes after intervention. Method of measurement: Pulse oximeter.;Respiratory rate. Timepoint: Baseline and 10 minutes after intervention. Method of measurement: Number of breaths per minute.;Heart rate. Timepoint: Baseline and 10 minutes after intervention. Method of measurement: Heart beats at per minute.;Arterial blood gases. Timepoint: Baseline and 10 minutes after intervention. Method of measurement: Arterial blood gases test.;Dyspnea Severity. Timepoint: Baseline and 10 minutes after intervention. Method of measurement: MMRC Dyspnea Severity Scale.

—

Secondary

Measure	Time frame
Crackles. Timepoint: Baseline and 10 minutes after intervention. Method of measurement: Stethoscope.;Wheezing. Timepoint: Baseline and 10 minutes after intervention. Method of measurement: Stethoscope.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBabak Mahshidfar

Iran University of Medical Sciences

mahshidfar.b@iums.ac.ir+98 21 6653 9255

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026